Here are four things to know:
1. Brean Capital currently has a “buy” rating on the stock.
2. NuVasive has a one-year low of $31.35 and a one-year high of $51.23.
3. The stock has a 50-day moving average of $47.23 and a 200-day moving average of $41.65.
4. NuVasive’s market cap is $2.139 billion.
More articles on devices:
Spine device company stock report: 5 key companies — Feb. 26
Invibio Spine’s PEEK-OPTIMA HA Enhanced shows promise
JMEA Corporation wins grant from Montgomery County’ economic development department
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
